We are live on ! Find out more
FTH

Faeth Therapeutics
FTH

30 hedge funds and large institutions have $68M invested in Faeth Therapeutics in 2026 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

13,104% more capital invested

Capital invested by funds: $515K → $68M (+$67.5M)

1,000% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 2

200% more funds holding

Funds holding: 10 → 30 (+20)

200% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 1

167.15% more ownership

Funds ownership: 3.83% → 170.97% (+167%)

Holders
30
Holders Change
+20
Holders Change %
+200%
% of All Funds
0.37%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
22
Increased
3
Reduced
1
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
VC
Vivo Capital
California
+$14.4M
2
CAM
Cormorant Asset Management
Massachusetts
+$6.12M
3
Millennium Management
Millennium Management
New York
+$2.93M
4
Franklin Resources
Franklin Resources
California
+$2.67M
5
SC
Stempoint Capital
New York
+$2.65M

Top Sellers

Rank Fund Capital Flow
1
IC
Ikarian Capital
Texas
-$300K
2
Citigroup
Citigroup
New York
-$3.14K
3
BP
BNP Paribas
France
-$59
Name Holding Trade Value Shares
Change 		Change in
Stake
VC
1
Vivo Capital
California
$22.8M +$14.4M +722,020 New
CAM
2
Cormorant Asset Management
Massachusetts
$9.65M +$6.12M +306,222 New
Millennium Management
3
Millennium Management
New York
$4.62M +$2.93M +146,565 New
Franklin Resources
4
Franklin Resources
California
$4.21M +$2.67M +133,506 New
SC
5
Stempoint Capital
New York
$4.19M +$2.65M +132,873 New
CP
6
Caligan Partners
New York
$3.97M +$2.52M +126,002 New
TECP
7
Trails Edge Capital Partners
Georgia
$3.94M +$2.5M +125,000 New
Marshall Wace
8
Marshall Wace
United Kingdom
$2.07M +$1.31M +65,730 New
Goldman Sachs
9
Goldman Sachs
New York
$1.94M +$1.23M +61,568 New
HF
10
HRT Financial
New York
$1.83M +$1.16M +58,001 New
SCM
11
Suvretta Capital Management
New York
$1.09M +$690K +34,549 New
Bank of America
12
Bank of America
North Carolina
$1.04M +$654K +32,719 +10,692%
Renaissance Technologies
13
Renaissance Technologies
New York
$1.01M +$410K +20,525 +178%
LGM
14
Logos Global Management
California
$946K +$599K +30,000 New
BFM
15
Boothbay Fund Management
New York
$823K +$522K +26,124 New
BHCM
16
Brevan Howard Capital Management
Jersey
$641K +$406K +20,333 New
FAM
17
Fred Alger Management
New York
$578K +$366K +18,337 New
Balyasny Asset Management
18
Balyasny Asset Management
Illinois
$511K +$324K +16,205 New
CCM
19
Catalio Capital Management
New York
$464K – – –
Geode Capital Management
20
Geode Capital Management
Massachusetts
$300K +$190K +9,501 New
Jane Street
21
Jane Street
New York
$280K +$177K +8,872 New
Morgan Stanley
22
Morgan Stanley
New York
$277K +$176K +8,785 +87,850%
VCM
23
Vanguard Capital Management
Pennsylvania
$244K +$155K +7,750 New
IC
24
Ikarian Capital
Texas
$200K -$300K -15,000 -70%
VFT
25
Vanguard Fiduciary Trust
Pennsylvania
$199K +$126K +6,307 New
1
2

FTH Hedge Fund Activity: Q1 2026 in Review

30 of the 8,128 institutional investors tracked by Wall St. Rank reported a position in Faeth Therapeutics (FTH) for Q1 2026, worth a combined $68M — up 13,104% from $515K a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new FTH positions and 2 closed out — a net gain of 20 holders — while 3 added to existing stakes and 1 trimmed.

The largest buyer was Vivo Capital, opening a new position worth an estimated $14.4M. The largest seller was Ikarian Capital, cutting an estimated $300K.

  • 30 institutional investors held Faeth Therapeutics (FTH) as of Q1 2026, up from 10 in Q4 2025.
  • Funds reported $68M of Faeth Therapeutics stock for Q1 2026, up 13,104% quarter-over-quarter.
  • 22 funds opened new Faeth Therapeutics positions in Q1 2026 and 2 closed out, a net change of +20 holders.
  • The largest Faeth Therapeutics buyer in Q1 2026 was Vivo Capital, an estimated $14.4M added.
  • The largest Faeth Therapeutics seller in Q1 2026 was Ikarian Capital, an estimated $300K sold.

Based on aggregated 13F filings for Q1 2026.